- PRO
140 has been shown effective in inhibiting the growth of a human colon
carcinoma cell line (SW480) in a prominent mouse model
- PRO
140 extended the lives of treated mice and reduced tumor growth by more
than 50 percent
- CytoDyn
was recently featured favorably in a report by a leading independent small
cap media portal
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently
announced exciting progress (http://ibn.fm/thpLl)
in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal
antibody, which has multiple therapeutic indications including treating HIV,
cancer and inflammatory conditions.
In preclinical studies conducted over the past year, PRO 140
was shown effective in inhibiting the growth of a human colon carcinoma cell
line (SW480) in a prominent mouse model. The statistically significant results
will provide a basis for the filing of an Investigational New Drug (IND)
application with the U.S. Food and Drug Administration for a clinical trial of
PRO 140 in colon carcinoma patients, which CytoDyn plans to file within the
next few weeks.
In the studies, two different strains of immuno-incompetent
mice were used to grow SW480 human tumor cells, with different doses of PRO 140
being used as part of the studies. The SW480 cell line was derived from a
patient with colon adenocarcinoma; like many human cancers, the cell line was
CCR5-positive.
In comparison with the control mice, the lives of the mice
treated with PRO 140 were extended, and tumor growth decreased by more than 50
percent, which was statistically significant. The results were dose-dependent
and were repeated in separate experiments. Preclinical studies that are
currently ongoing are defining the mechanisms involved in PRO 140’s anti-tumor
efficacy.
CytoDyn believes that CCR5 is a crucial receptor in the
growth and invasiveness of human malignancies, and that premise is supported by
these studies. In addition to CytoDyn’s recent announcement regarding PRO 140’s
potential in metastatic breast cancers (http://ibn.fm/cCHM1), the company believes that these
results in colon cancer further support that, if approved, PRO 140 may offer
patients with breast and colon cancers an important potential therapeutic
option.
In addition to filing an IND to commence studies of PRO 140
for treating colon carcinoma, CytoDyn will continue exploring the biological
pathways involving CCR5 to identify other potential therapeutic applications
for PRO 140.
In other news from CytoDyn, a favorable report about the
company was recently published (http://ibn.fm/wXIwz)
by leading independent small cap media portal EmergingGrowth.com. The report
detailed the disruptive potential of PRO 140 in targeting HIV, along with its
other potential clinical applications, and also discussed CytoDyn’s market
valuation and current undervalued status.
In further company news, CytoDyn has noted that, upon the
closing of its proposed acquisition of ProstaGene, Richard G. Pestell, Ph.D,
M.D., is expected to be appointed as CytoDyn’s chief medical officer. Pestell
is currently serving as the CEO of ProstaGene and as president of the
Pennsylvania Cancer and Regenerative Medicine Research Center.
CytoDyn has also appointed Michael A. Klump, president and
CEO of Argonne Capital Group, to its board of directors, as noted in a recent
press release (http://ibn.fm/toYyP).
For more information, visit the company’s website at www.CytoDyn.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment